When should gadolinium dose information be included in an MRI report?

When should gadolinium dose information be included in an MRI report?

• A. Never include dose information
• B. If gadolinium-based contrast is used, report the agent and dose
• C. Only note whether contrast was used, not the dose
• D. Include dose information only if the patient has kidney disease

Answer: (C)

When writing an MRI report, the essential point about gadolinium is whether contrast was used, not the exact amount administered. The diagnostic content relies on how enhancement may affect lesion conspicuity and interpretation, while the precise dose is administrative data tied to the contrast administration record rather than the radiology report itself. Keeping dose information out of the report avoids duplication and potential transcription errors; the dose is recorded separately in the order/administration log and can be consulted if needed. Some guidelines emphasize documenting that contrast was used and, if relevant to interpretation, the general agent type—but the exact dose does not belong in the diagnostic narrative. The other choices would either push dose details into the report (which can cause confusion) or rely on dose-based conditions that aren’t how reporting practice is standardized.

When writing an MRI report, the essential point about gadolinium is whether contrast was used, not the exact amount administered. The diagnostic content relies on how enhancement may affect lesion conspicuity and interpretation, while the precise dose is administrative data tied to the contrast administration record rather than the radiology report itself. Keeping dose information out of the report avoids duplication and potential transcription errors; the dose is recorded separately in the order/administration log and can be consulted if needed.

Some guidelines emphasize documenting that contrast was used and, if relevant to interpretation, the general agent type—but the exact dose does not belong in the diagnostic narrative. The other choices would either push dose details into the report (which can cause confusion) or rely on dose-based conditions that aren’t how reporting practice is standardized.